Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-120189
- The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually chemoradiotherapy based. We report the case of a 46-year-old patient with an unresectable, locally advanced pancreatic cancer (pT4 Nx cM0 G2) who was treated with a sequential neoadjuvant chemotherapy regimen consisting of 2 cycles of nab-paclitaxel plus gemcitabine followed by 4 cycles of FOLFIRINOX.The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually chemoradiotherapy based. We report the case of a 46-year-old patient with an unresectable, locally advanced pancreatic cancer (pT4 Nx cM0 G2) who was treated with a sequential neoadjuvant chemotherapy regimen consisting of 2 cycles of nab-paclitaxel plus gemcitabine followed by 4 cycles of FOLFIRINOX. Neoadjuvant chemotherapy resulted in secondary resectability (R0 resection). After 2 cycles of nab-paclitaxel plus gemcitabine, the patient already had a complete metabolic remission as measured by integrated fludeoxyglucose ((18)F) positron emission tomography and computerized tomography. After a follow-up of 18 months the patient is alive without progression of disease. We propose to assess the clinical benefit of sequencing the combinations nab-paclitaxel plus gemcitabine and FOLFIRINOX as neoadjuvant therapy for patients with locally advanced and initially unresectable pancreatic cancer in a controlled clinical trial.…
Autor(en): | Volker Kunzmann, Ken Herrmann, Christina Bluemel, Markus Kapp, Ingo Hartlapp, Ulrich Steger |
---|---|
URN: | urn:nbn:de:bvb:20-opus-120189 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) |
Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin | |
Medizinische Fakultät / Medizinische Klinik und Poliklinik II | |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Case Reports in Oncology |
ISSN: | 1662-6575 |
Erscheinungsjahr: | 2014 |
Band / Jahrgang: | 7 |
Heft / Ausgabe: | 3 |
Seitenangabe: | 648-55 |
Originalveröffentlichung / Quelle: | Case Reports in Oncology 2014;7:648–655 DOI: 10.1159/000367966 |
DOI: | https://doi.org/10.1159/000367966 |
PubMed-ID: | https://pubmed.ncbi.nlm.nih.gov/25408659 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 616 Krankheiten |
Freie Schlagwort(e): | 5-Fluorouracil; folinic acid; gemcitabine; irinotecan; locally advanced disease; nab-paclitaxel; neoadjuvant chemotherapy; oxaliplatin; pancreatic cancer |
Datum der Freischaltung: | 11.02.2016 |
Lizenz (Deutsch): | CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell |